Celularity Inc Dr News Today

The Placental Stem Cell Advantage As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy? Last month, Celularity announced that the FDA granted Orphan Drug Designation status to the company’s lead therapeutic candidate, CYNK-001, for the treatment of malignant gliomas. ...